admitted to a university medical center between 1995 and 2001 were identified, and patient charts were retrospectively reviewed. Neuroimaging and intensive care unit records were available for all patients. Patient demographics, clinical status on admission, location of a ruptured aneurysm, severity of the SAH blood clot load, white blood cell count on post-SAH Days 1 through 5, postoperative administration of steroid agents, history of Type I or II diabetes, occurrence of hydrocephalus or fever prior to vasospasm, date of aneurysm treatment (including surgical clip application and/or coil placement), and occurrence of vasospasm were recorded. The patient's clinical condition at admission was graded according to the Hunt and Hess classification system. 11 The severity of SAH was demonstrated on the initial CT scan and classified according to the scale of Fisher, et al. 7 Excluding causes of neurological worsening displayed on CT scanning (such as rebleeding or hydrocephalus) and other identifiable causes of such worsening (for example, electrolyte disturbances, surgical morbidity, hypoxia, seizures, or any other systemic pathology); the onset of confusion or disorientation; a decline in the level of consciousness; or a focal neurological deficit occurring 3 to 14 days after SAH, as previously described, 10 was classified as a symptomatic clinical vasospasm only when supported by one of the following: 1) arterial narrowing demonstrated on angiography; 2) TCD ultrasonography flow velocities indicative of vasospasm (Ͼ 180 cm/second); or 3) acute reversal of deficits with the administration of hypervolemiahypertension therapy.
Treatment of Aneurysmal SAH
During the review period, several treatment parameters were standard for all patients with SAH who were admitted to our institution. Diagnostic cerebral angiography was performed during the first 24 hours after admission. Nimodipine, phenytoin, and gastrointestinal prophylaxis (H 2 -blockers or proton pump inhibitors) were administered on the day of admission and continued throughout the patient's stay in the intensive care unit. Decadron was administered preoperatively and tapered immediately after surgery. The subset of patients in whom Decadron was not tapered during the 1st week postsurgery was classified as having received postoperative steroid therapy. Patients with no evidence of vasospasm remained euvolemic. At the onset of symptomatic vasospasm, hypervolemia-hypertension therapy was maximized by maintaining pulmonary wedge pressures between 16 and 18 mm Hg based on invasive hemodynamic monitoring in all patients.
Statistical Analysis
The significance of differences in continuous variables was determined using the Student t-test. Nonparametric data were compared using the Mann-Whitney U-test, and frequencies with the chi-square test. Variables found to be significant in a univariate analysis were included in a multivariate logistic regression model (StatView 5.0; SAS Institute, Cary, NC). Because patient age, ruptured ICA or ACA aneurysm, Hunt and Hess grade, and Fisher grade have been reported to be associated with the development of cerebral vasospasm, these variables were also included in the multivariate logistic regression model. 4, 7, 27, 28 
Results
Two hundred twenty-four patients with SAH were admitted to our institution between 1995 and 2001. Ninety-nine patients (44%) were male and 125 (56%) were female. The mean patient age among those who developed vasospasm was 53 Ϯ 14 years. On admission, 120 patients (54%) had a Hunt and Hess grade of III or higher, and 75 (33%) patients had a Fisher Grade 3. One hundred fifty-four patients (69%) underwent craniotomy for the treatment of an aneurysm, 32 (14%) underwent endovascular coil insertion, and 38 (17%) demonstrated no evidence of an aneurysm on neuroimaging. The source of the SAH was localized to an anterior circulation aneurysm in 139 patients (62%) and to a posterior circulation aneurysm in 47 patients (21%). Eighty-one patients (36%) were admitted for chronic essential hypertension, and 16 (7%) with a diagnosis of diabetes mellitus. Forty-six patients (20%) developed hydrocephalus following SAH and 36 (16%) received steroid agents following surgery.
One hundred one (45%) patients developed symptomatic cerebral vasospasm. Its diagnosis was demonstrated on cerebral angiography in 71 patients, TCD ultrasonography in 17 patients, and response to hypervolemia-hypertension therapy in 13 patients. The mean onset of symptomatic vasospasm was 5.8 Ϯ 3 days following SAH. The mean patient age among those who developed vasospasm was 53 Ϯ 14 years.
As demonstrated in previous studies, patients who developed symptomatic vasospasm more often exhibited a Hunt and Hess Grade III or higher (p = 0.015) and a Fisher Grade 3 SAH (p = 0.001) on admission (Table 1 ). In addition, those who developed symptomatic vasospasm had a higher peak leukocyte count within the first 5 days of SAH (p = 0.001; Table 1 and Fig. 1 ). The largest difference in the median leukocyte count in patients with and without vasospasm occurred 3 days after SAH. Patients who did not have symptomatic vasospasm were more likely to have nonaneurysmal SAH (p = 0.001) or a PCA aneurysm (p = 0.002). Patient age and sex, method of aneurysm stabilization, location of the aneurysm (other than those located on the PCA), development of fever or hydrocephalus, a history of hypertension or diabetes mellitus, and continued administration of steroid agents were not associated with the development of symptomatic vasospasm.
There were four independent risk factors for symptomatic vasospasm (Table 2) . Patients with a Fisher Grade 3 SAH had a 7.5-fold (p Ͻ 0.001) increased likelihood of developing symptomatic vasospasm. Furthermore, each increase of 1000 ϫ 10 9 /L in the serum leukocyte count was associated with a 9% increase (p Ͻ 0.01) in the likelihood of the subsequent onset of a symptomatic vasospasm. Peak leukocyte count remained independently associated with symptomatic vasospasm in our analysis of only those patients with aneurysmal SAH (p Ͻ 0.01). A peak serum leukocyte count greater than 15 ϫ 10 9 was associated with a 3.3-fold increase in the likelihood of developing symptomatic vasospasm (p Ͻ 0.001). Patients with spontaneous SAH or ruptured PCA aneurysms were sevenfold (p Ͻ 0.001) and 20-fold (p Ͻ 0.005) less likely to develop symptomatic vasospasm, respectively. Although the patient's Hunt and Hess grade on admission was associated with symptomatic vasospasm in univariate analysis, a higher Hunt and Hess grade did not independently increase the likelihood of its development in a multivariate analysis.
Discussion
This is the first study in which leukocytosis is described as an independent risk factor for the development of cerebral vasospasm. In this 7-year review of 224 consecutive patients with SAH, a Fisher Grade 3 hemorrhage and serum leukocytosis within the first 5 days after SAH were independent risk factors for the development of cerebral vasospasm. Although the Hunt and Hess grade was associated with the onset of vasospasm in a univariate analysis, this association was not statistically significant when adjusting for the blood clot size. The occurrence of spontaneous nonaneurysmal SAH or the rupture of a PCA aneurysm was independently associated with a reduced risk of developing vasospasm. Patient age, occurrence of fever, development of hydrocephalus, craniotomy compared with endovascular aneurysm stabilization, continued administration of postoperative steroid agents, and preexisting comorbidities such as hypertension or diabetes mellitus were not associated with the development of cerebral vasospasm.
The incidence of symptomatic vasospasm in this series (45%) is higher than in many previously reported studies (20-40%). 5, 6, 12, 16, 24, 32 Angiography studies alone may not be sensitive enough for classifying neurological deficits related to vasospasm, a fact supported by growing evidence that distal artery vasospasm and microcirculation pathology may also play a role in this complex disease. 23, 25 Therefore, we also used TCD ultrasonography velocities and patient response to hypervolemia-hypertension therapy to classify delayed neurological deficits as related to vasospasm. In contrast to our experience, many investigators in other studies have not defined transient neurological symptoms that are quickly reversed by hypervolemia-hypertension therapy as vasospasm and have only included more lasting deficits, a practice that may have contributed to a slightly greater incidence of symptomatic vasospasm in our series.
Based on data from prior studies, Fisher Grade 3 SAH consistently is associated with an increased risk of cerebral vasospasm. 1, 7, 20, 27 Similarly, a Fisher Grade 3 SAH was the strongest risk factor for the development of vasospasm in our series. Although the presence of fever subsequent to SAH has been shown to increase independently the risk of developing vasospasm, 24, 36 fever was not an independent risk factor in our study. The relationship between the location of a ruptured aneurysm and vasospasm is less clear. Ruptured ACA and ICA aneurysms have been found to increase the risk of subsequent vasospasm; 27, 29 however, Bonilha, et al., 3 demonstrated no difference in the incidence of vasospasm as a function of aneurysm location. In our series of patients, bleeding of PCA aneurysms had a very low association with the incidence of vasospasm.
Researchers assessing clinical status, patient age, and endovascular aneurysm stabilization as risk factors for vasospasm have also yielded conflicting results. Both a strong 3, 28 and an absent 1 association between Hunt and Hess grade and development of vasospasm have been reported. Our results indicate that the higher incidence of vasospasm in patients with higher Hunt and Hess grades may be an effect of concomitantly larger SAHs. Yalamanchili, et al., 37 originally described a lower rate of vasospasm following endovascular aneurysm coil placement. Although data from the International Subarachnoid Aneurysm Trial demonstrated an absolute risk reduction of 6.9% in the morbidity rate, favoring the endovascular treatment group, 19 a difference in the incidence of vasospasm was not reported. Results of recent studies are consistent with our finding that endovascular stabilization does not influence the risk of vasospasm. 4, 8, 9, 13 Both increasing 14 and decreasing patient age 4, 28 have been implicated as risk factors for the development of vasospasm. In our series, there was no association between patient age and vasospasm. We report on the first multivariate study revealing that leukocytosis is an independent risk factor for the development of cerebral vasospasm. Neil-Dwyer and Cruickshank 21 first demonstrated the prognostic significance of leukocytosis in the outcome of patients with SAH. Parkinson and Stephensen 26 described increased rates of death in patients with leukocytosis following SAH. Maiuri, et al., 17 observed a similar association and hypothesized that arterial spasm may account for this association. In contrast, Spallone, et al., 33 found no association between admission leukocyte count and risk of subsequent ischemic complications. More recently, increased serum leukocyte counts have been reported in patients who developed vasospasm after aneurysmal SAH; 22, 36, 38 however, investigators in these studies did not adjust for confounding variables and therefore cannot assess an independent association between leukocyte count and cerebral vasospasm. In our series we reveal that leukocytosis is a risk factor for the subsequent onset of vasospasm, which is independent of blood clot load or location, clinical status, or patient age. Because postoperative steroid agents or infection may also increase serum leukocyte counts, we adjusted for steroid use and the occurrence of fever in our analysis. Of course, our study is retrospective in nature and relatively small in sample size; thus, further prospective trials are warranted to confirm our observations.
Because serum levels were assessed within the first 5 days after SAH and peak leukocyte levels were recorded only prior to the onset of vasospasm, the observed association carries potential diagnostic use. Daily monitoring of the serum leukocyte count is typically included as postoperative management in patients with SAH and therefore represents a potentially convenient marker for assessing the risk of vasospasm. Measuring the leukocyte count throughout the entire vasospasm risk period may further increase its usefulness. Significant leukocytosis may identify patients who should undergo more frequent imaging studies (TCD ultrasonography, spiral CT scanning, or angiography) and may signify those who could benefit from more aggressive hypertension, hypervolemia, and hemodilution therapy or early angioplasty.
Conclusions
This analysis of patients treated for SAH at our institution during a 7-year period revealed that leukocytosis independently increased the risk of developing vasospasm. In contrast, aneurysm rupture at the PCA and spontaneous SAH decreased the likelihood of developing vasospasm. Leukocytosis may represent a convenient marker of increased risk of cerebral vasospasm after SAH, which could potentially influence treatment of these patients. Further prospective trials are warranted to confirm our observation.
